Is GSK prepping a $1bn takeover bid for IDRx? | pharmaphorum
23 hours ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 ...
1 day ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial ...
GSK's Shingrix New Prefilled Syringe Presentation Accepted For …
36 minutes ago · (RTTNews) - British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the regulatory application of a prefilled syringe presentation ...
GSK nears $1bn deal for biotech developing drug for rare tumour
1 day ago · GSK nears $1bn deal for biotech developing drug for rare tumour ... Share News Tips Securely Individual Subscriptions Professional Subscriptions Republishing Executive Job Search Advertise with ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
FDA Grants Breakthrough Therapy Designation For GSK's GSK'227 …
2 days ago · (RTTNews) - GSK plc (GSK), a pharmaceutical and biotechnology company, on Tuesday announced that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation for GSK ...
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
Press releases | GSK US
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines. Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. Studies from OPERA and Trio cohorts provide further real-world evidence.
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines.
GSK plc (GSK) Latest Press Releases & Corporate News - Yahoo …
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.